Trending...
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- EFA Announces 2026 Editorial Rate Chart
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
BETHLEHEM, Pa.--(BUSINESS WIRE)--Saladax Biomedical, Inc. (Saladax) is pleased to announce that it has acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families and has resulted in 33 U.S. patents and 296 patents in ex-U.S. countries. This IP, along with the current Saladax IP, covers the major antipsychotic drugs that are prescribed worldwide and places Saladax in a premier position in the antipsychotic drug testing field.
With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time.
SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1
More on The PennZone
Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products.
"This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM)." stated Sal Salamone, Founder and CEO of Saladax. "The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980's."
About Saladax Biomedical, Inc.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
Contacts
More on The PennZone
Saladax Biomedical, Inc.
Salvatore Salamone
ssalamone@saladax.com
With this IP portfolio, Saladax has developed tests for chemistry analyzers commonly found in hospitals and a point-of-care instrument that can be used where centralized testing is not possible. These tests address a significant unmet clinical need for patients with serious mental illness (SMI) by providing rapid, actionable results to health care professionals (HCP). International and U.S. clinical guidelines have recently been established recommending antipsychotic drug testing. The availability of these tools will greatly enhance the ability of health care professionals to better manage their patients in real time.
SMI is a significant public health concern. The estimated economic impact of SMI worldwide is more than $2.5 trillion each year with the number of people that SMI affects growing rapidly. In the U.S. current data shows that more than 13 million adults in the U.S. experienced SMI in the past year. That is more than 3% of the adult population.1
More on The PennZone
- On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
- Burkentine Builders Breaks Ground on Their 100,000-Square-Foot Warehouse in Shippensburg, PA
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- Pine Creek Rail Trail Named Pennsylvania's 2026 Trail of the Year
- DC Accounting Firm Offers Free Business CRM to Small Business Clients Alongside Weekly Bookkeeping Model
Saladax is well positioned as the leading diagnostic company in the field of antipsychotic drug testing with a full panel of antipsychotic tests already on the market and a solid pipeline of new products.
"This is a very exciting time for Saladax and the field of therapeutic drug monitoring (TDM)." stated Sal Salamone, Founder and CEO of Saladax. "The availability of antipsychotic testing is arguably the most significant step in the field of TDM since the launch of the Abbott Diagnostics TDx platform back in the 1980's."
About Saladax Biomedical, Inc.
Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.
- Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
- Bessonova L, Ogden K, The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature review 2011. doi: 10.2147/CEOR.S259338
Contacts
More on The PennZone
- CCHR: Psychiatric Drugs Fuel Rising Death Toll: National Adverse Drug Event Awareness Day Confronts America's Medication Crisis
- Explosive $10 Billion Counter-Drone Market with AI-Powered Defense Ecosystem: ZenaTech, Inc. (N A S D A Q: ZENA)
- High-Value Execution Phase Begins: Bitcoin Bancorp Ignites Texas Rollout of Digital Asset ATM Network: Bitcoin Bancorp (Stock Symbol: BCBC) $BCBC
- Women's Wellness Conference Returns with a Powerful Call to Restoration
- UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
Saladax Biomedical, Inc.
Salvatore Salamone
ssalamone@saladax.com
Filed Under: Business
0 Comments
Latest on The PennZone
- Rhys-Davies, Wright, Norris, Jacinto Highlight Latest Wave of FAN EXPO Philadelphia Celebrity Guests
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
- Genpak Announces Closure of Utah Manufacturing Facility
- Newborn Care Network Introduces Clinical Standard to Bridge the Six-Week Postpartum Gap
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- Monexplora Explains the Options Mechanics Behind March's Tech Selloff and VIX Surge
- Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
- New Book Reveals The Science Of Predictions
- Compliance Alert: Maryland, Texas Regulate Use of Artificial Intelligence in Utilization Reviews
- Colony Ridge Communities Celebrates Successful Soccer Season Kickoff with Families and Youth
- Best Companies Group Free Launches Best Places to Work in Michigan Program
- Billy Bob Thornton & The Boxmasters Coming to The Eichelberger Performing Arts Center This August
- NYC Composer/Educator Launches Debut Children's Book to Fantastic Reviews
- EFA Announces 2026 Editorial Rate Chart
- Red5 Taps PubNub to Power the Next Era of Real-Time Interactive Streaming
- Shoutout Joseph Neibich aka Nybyk
- Meet Joseph Neibich aka Joseph Nybyk of Beachwood Canyon
- LARUS Launches Business Continuity Framework for IPv4-Dependent Networks
- KeysCaribbean Offers 'Skip-the-Crowds' Savings With 15 Percent Off April Stays
- Supply & Demand Chain Executive Names Puga Sankara as Recipient of 2026 Pros to Know Award